No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Specializing in regenerative tissue medicine, L&C BIO Co., Ltd. operates as a dedicated research and development enterprise. The company's diverse product range encompasses human tissue products, various medical devices, and a selection of cosmetic solutions. Established in 2011, this firm is headquartered in Seongnam, South Korea.
www.lncbio.co.krNo one on the platform currently holds 290650.KQ.
No tracked institution reports a position in 290650.KQ as of their last filing.
No one on the platform has traded 290650.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 18.6% | 21.0% | ||||
| Profit Margin % | -161.7% | 28.6% | 26.3% | |||
| Free Cash Flow Margin % | -3.8% | -32.3% | -12.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $167.8B | +94.6% | $533.91 | $384.02–$681.96 | — | 1 |
| 2027 | $263.2B | +56.8% | $1959.77 | $1501.64–$2341.16 | — | 4 |
| 2028 | $341.4B | +29.7% | $2865.41 | $2061.00–$3660.01 | — | 2 |
| 2029 | $1.03T | +202.1% | $0.00 | $0.00–$0.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 290650.KQL&C Bio Co., Ltd | $46200.00 | +1.09% | $1.14T | — |
| 005690.KSPharmicell Co., Ltd. | $12160.00 | +4.56% | $729.6B | — |
| 006280.KSGC Biopharma Corp. | $123600.00 | +0.98% | $1.41T | — |
| 039200.KQOscotec Inc. | $36000.00 | +4.80% | $1.38T | — |
| 069620.KSDaewoong pharmaceutical Co.,Ltd | $111700.00 | +2.57% | $1.29T | — |
| 085660.KQChabiotech Co.,Ltd. | $7840.00 | +0.13% |
Source: Financial Modeling Prep · peers by sector/industry
| $725.2B |
| — |
| 096530.KQSeegene, Inc. | $33150.00 | +2.16% | $1.51T | — |